Prot# 2689-CL-2004: A Phase 2, Randomized, Open-Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

Project: Research project

Project Details

StatusFinished
Effective start/end date5/30/12 → 5/30/18

Funding

  • Astellas Pharma Global Development, Inc. (2689-CL-2004)